Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Equity Average: 2011-2025

Historic Equity Average for Iovance Biotherapeutics (IOVA) over the last 8 years, with Sep 2025 value amounting to $700.4 million.

  • Iovance Biotherapeutics' Equity Average fell 9.16% to $700.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $700.4 million, marking a year-over-year decrease of 9.16%. This contributed to the annual value of $647.5 million for FY2024, which is N/A change from last year.
  • Latest data reveals that Iovance Biotherapeutics reported Equity Average of $700.4 million as of Q3 2025, which was down 4.47% from $733.2 million recorded in Q2 2025.
  • In the past 5 years, Iovance Biotherapeutics' Equity Average ranged from a high of $771.0 million in Q3 2024 and a low of $511.0 million during Q1 2023.
  • In the last 3 years, Iovance Biotherapeutics' Equity Average had a median value of $700.4 million in 2025 and averaged $675.6 million.
  • Its Equity Average has fluctuated over the past 5 years, first rose by 23.75% in 2024, then decreased by 9.16% in 2025.
  • Iovance Biotherapeutics' Equity Average (Quarterly) stood at $629.3 million in 2023, then climbed by 17.90% to $741.9 million in 2024, then decreased by 9.16% to $700.4 million in 2025.
  • Its Equity Average stands at $700.4 million for Q3 2025, versus $733.2 million for Q2 2025 and $739.1 million for Q1 2025.